康诺亚生物医药科技(成都)有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Keymed Biosciences Announces 2023 Annual Results and Business Updates 2024-03-27 01:16
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration 2023-03-18 08:00
Keymed and Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement with AstraZeneca for CMG901 2023-02-23 13:01
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM 2023-01-18 09:52
China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer 2022-09-22 13:05
Keymed Biosciences Announces Dosing of First Patient in Phase I Trial of Bispecific Antibody CM350 2022-06-10 18:42
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies 2022-04-20 10:27
CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States 2022-04-12 15:45
Keymed Biosciences Releases 2021 Annual Results 2022-03-30 23:41
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect 2022-03-07 15:57
Keymed Bio Joins Hang Seng Family of Indexes 2022-02-18 22:10
1